These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
400 related articles for article (PubMed ID: 10471051)
21. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03. Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437 [TBL] [Abstract][Full Text] [Related]
23. [A case of triple malignancies (gastric cancer, lung cancer and malignant pleural mesothelioma) after asbestos exposure]. Kishimoto T Nihon Kokyuki Gakkai Zasshi; 2003 Apr; 41(4):304-9. PubMed ID: 12795187 [TBL] [Abstract][Full Text] [Related]
24. Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer. Hirao T; Nelson HH; Ashok TD; Wain JC; Mark EJ; Christiani DC; Wiencke JK; Kelsey KT Cancer Res; 2001 Jan; 61(2):612-5. PubMed ID: 11212258 [TBL] [Abstract][Full Text] [Related]
25. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560 [TBL] [Abstract][Full Text] [Related]
26. Serum levels of pantropic p53 protein and EGF-receptor, and detection of anti-p53 antibodies in former uranium miners (SDAG Wismut). Schneider J; Presek P; Braun A; Woitowitz HJ Am J Ind Med; 1999 Dec; 36(6):602-9. PubMed ID: 10561680 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions. Toumbis M; Rasidakis A; Passalidou E; Kalomenidis J; Alchanatis M; Orphanidou D; Jordanoglou J Anticancer Res; 1996; 16(4A):2101-4. PubMed ID: 8712750 [TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma. Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803 [TBL] [Abstract][Full Text] [Related]
29. Serum anti-p53 autoantibodies from patients with idiopathic pulmonary fibrosis associated with lung cancer. Oshikawa K; Sugiyama Y Respir Med; 2000 Nov; 94(11):1085-91. PubMed ID: 11127496 [TBL] [Abstract][Full Text] [Related]
30. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Ralhan R; Nath N; Agarwal S; Mathur M; Wasylyk B; Shukla NK Clin Cancer Res; 1998 Sep; 4(9):2147-52. PubMed ID: 9748133 [TBL] [Abstract][Full Text] [Related]
31. Tissue polypeptide antigen in bronchogenic carcinoma. Zatloukal P; Glagolicová A; Linhart M; Sebes A; Hencl P; Mĕricka O Neoplasma; 1993; 40(5):301-3. PubMed ID: 8272159 [TBL] [Abstract][Full Text] [Related]
32. First report of asbestos-related diseases in Hong Kong. Lam WK; Kung TM; Ma PL; So SY; Mok CK Trop Geogr Med; 1983 Sep; 35(3):225-9. PubMed ID: 6316591 [TBL] [Abstract][Full Text] [Related]
33. Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Wang X; Christiani DC; Wiencke JK; Fischbein M; Xu X; Cheng TJ; Mark E; Wain JC; Kelsey KT Cancer Epidemiol Biomarkers Prev; 1995; 4(5):543-8. PubMed ID: 7549812 [TBL] [Abstract][Full Text] [Related]
34. P53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy. Bergqvist M; Brattström D; Larsson A; Holmertz J; Hesselius P; Rosenberg L; Wagenius G; Brodin O Anticancer Res; 1998; 18(3B):1999-2002. PubMed ID: 9677456 [TBL] [Abstract][Full Text] [Related]
35. Anti-p53 antibodies in serum of smokers and head and neck cancer patients. Wollenberg B; Jan NV; Pitzke P; Reiter W; Stieber P Anticancer Res; 1997; 17(1A):413-8. PubMed ID: 9066686 [TBL] [Abstract][Full Text] [Related]
36. SV40-like DNA sequences in pleural mesothelioma, bronchopulmonary carcinoma, and non-malignant pulmonary diseases. Galateau-Salle F; Bidet P; Iwatsubo Y; Gennetay E; Renier A; Letourneux M; Pairon JC; Moritz S; Brochard P; Jaurand MC; Freymuth F J Pathol; 1998 Mar; 184(3):252-7. PubMed ID: 9614376 [TBL] [Abstract][Full Text] [Related]
37. Risk factors of lung cancer by histological category in Taiwan. Ger LP; Hsu WL; Chen KT; Chen CJ Anticancer Res; 1993; 13(5A):1491-500. PubMed ID: 8239527 [TBL] [Abstract][Full Text] [Related]
38. [Antibody formation to cellular p53 protein in patients with squamous cell carcinomas of the upper respiratory and digestive system]. Maass JD; Gottschlich S; Lippert BM; Niemann AM; Görögh T; Werner JA Laryngorhinootologie; 1996 Jan; 75(1):53-6. PubMed ID: 8851121 [TBL] [Abstract][Full Text] [Related]
39. A new prognostic indicator for head and neck cancer--p53 serum antibodies? Gottschlich S; Folz BJ; Goeroegh T; Lippert BM; Maass JD; Werner JA Anticancer Res; 1999; 19(4A):2703-5. PubMed ID: 10470224 [TBL] [Abstract][Full Text] [Related]
40. Association of serum reactive oxygen metabolite levels with different histopathological types of lung cancer. Gencer M; Ceylan E; Aksoy N; Uzun K Respiration; 2006; 73(4):520-4. PubMed ID: 16432293 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]